Novartis Sales Growth Tests the Pharma Patent Cliff
Novartis gave health investors a clean case study in the patent cliff problem on July 21, 2026. Sales grew again in Q2, but the route was not smooth. New medicines had to run hard just to offset copycat pressure on older blockbusters.
The headline number was USD 14.4 billion of quarterly net sales. That was up 3 percent in dollars and 1 percent at constant currencies. Not spectacular, but after a weak first quarter, positive growth matters. In big pharma, one percent can be the difference between a stable bridge and a hole in the model.
New brands did the heavy lifting
The arithmetic was blunt. Volume growth added 18 percentage points to Q2 sales. Generic competition removed 14 percentage points. Pricing took away another 3 percentage points, while currency added 2 percentage points. That leaves a narrow gain, not because demand was weak, but because old exclusivity is expensive when it disappears.
Kisqali was the largest growth engine. The breast cancer drug delivered USD 1.70 billion of Q2 sales, up 43 percent at constant currencies. The company pointed to market share gains in early breast cancer and continued strength in metastatic disease. For a pharma model, that is the useful kind of growth. It comes from a product with expanding clinical relevance, not only from price.
Kesimpta also helped. The multiple sclerosis treatment produced USD 1.42 billion of sales, up 32 percent at constant currencies. Scemblix, used in chronic myeloid leukemia, reached USD 562 million and grew 89 percent. Pluvicto, the radioligand therapy for prostate cancer, reached USD 651 million and rose 43 percent.
The patent cliff is still visible
Entresto shows the other side of the distribution. The heart failure medicine produced USD 1.18 billion of Q2 sales, down 51 percent at constant currencies. That is what generic entry looks like when it moves from theory into revenue. The market does not politely taper when exclusivity ends.
Promacta and Revolade also fell hard, with Q2 sales of USD 179 million, down 65 percent at constant currencies. Tasigna reached USD 142 million, down 58 percent. Xolair declined 25 percent. The old base is not collapsing all at once, but enough blocks are shrinking to keep management honest.
For the first half, net sales were USD 27.5 billion. That was up 1 percent in dollars, but down 2 percent at constant currencies. Core operating income fell 7 percent at constant currencies in the first half. The quarter improved, yet the half year still carries the cost of earlier erosion.
This is why full year guidance stayed cautious. Novartis still expects low single digit sales growth at constant currencies and a low single digit decline in core operating income. The market often wants a clean recovery story. The actual company gave a more useful answer: growth is back, margins are not fully repaired.
Regulators moved several programs forward
The Q2 update was not only an income statement. It also included several regulatory events that matter for the next sales curve. Rhapsido received European Commission and Japan approval for chronic spontaneous urticaria in adults who do not respond well enough to H1 antihistamine treatment. It is an oral Bruton tyrosine kinase inhibitor, which gives the launch a clear clinical niche.
Itvisma received European Commission approval for a broader spinal muscular atrophy population. The therapy is aimed at people two years and older with 5q spinal muscular atrophy and a bi allelic mutation in the SMN1 gene. That matters because gene replacement therapy economics are lumpy. A broader label can change the addressable patient pool quickly.
Fabhalta received traditional FDA approval in July for adults with primary immunoglobulin A nephropathy at risk of progression. The kidney disease market has become more active as companies try to slow loss of function before dialysis becomes the expensive endpoint. In that setting, hard renal outcomes will matter more than elegant mechanism slides.
Trial data keeps the pipeline credible
Rhapsido had Phase III data in chronic inducible urticaria. The study met its primary endpoint across the three most common subtypes, with higher complete response rates at Week 12. Responses appeared as early as Week 2 in two subtypes. A separate extension study in chronic spontaneous urticaria showed a 72 percent lower relapse risk for patients who continued treatment compared with those switched to placebo.
Pluvicto added prostate cancer data from the Phase III PSMAddition study. Subgroup results showed consistent improvement in radiographic progression free survival across disease volume and presentation. Earlier data showed a 28 percent reduction in the risk of progression or death. Further results showed a 58 percent reduction in the risk of PSA progression.
Cosentyx delivered Phase III data in polymyalgia rheumatica. The study showed statistically significant sustained remission at Week 52 versus placebo, doubled remission rates, and reduced cumulative glucocorticoid exposure. That is clinically relevant because steroid exposure is not free. Patients pay for it in bone, glucose, infection risk, and time.
There were also late and early stage signals in kidney disease, rare muscle disease, leukemia, breast cancer, and Huntington disease. Some will fail. That is normal. The useful point is that Novartis is not relying on one miracle asset to fill the revenue gap.
Balance sheet choices tighten the frame
Free cash flow was USD 5.6 billion in Q2, down 12 percent. In the first half it was USD 8.9 billion, down 9 percent. That is still a large cash engine, but the direction matters because pharma uses cash in many places at once: research, acquisitions, dividends, buybacks, and manufacturing scale.
Net debt rose to USD 39.4 billion at June 30, 2026, from USD 21.9 billion at the end of 2025. The increase came as free cash flow was more than offset by acquisitions and other asset deals, the annual dividend, and treasury share transactions. That is not automatically bad. It does mean capital allocation is now part of the health story, not a footnote after the science.
What this means
Novartis Q2 2026 is a reminder that pharma growth is a replacement rate problem. New brands must scale faster than old products decay. In this quarter, they did. Over the first half, the pressure is still visible.
The next useful data points are not slogans about innovation. Watch whether Kisqali, Kesimpta, Scemblix, Pluvicto, Leqvio, and Fabhalta can keep growing while Entresto and other exposed brands decline.
For investors and health system observers, this is the practical lesson. A patent cliff is not a cliff if the bridge is already built. It is a cliff if the bridge exists only in slide decks.